OncoMatch/Clinical Trials/NCT07220616
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Is NCT07220616 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including DS3790a and Combination drug for hematological malignancies.
Treatment: DS3790a · Combination drug · Combination drug — This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic stem cell transplant
Prior Allo-SCT.
Cannot have received: solid organ transplantation
Prior solid organ transplantation.
Lab requirements
Blood counts
adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to initiation of trial intervention as specified in the protocol
Kidney function
adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to initiation of trial intervention as specified in the protocol
Liver function
adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to initiation of trial intervention as specified in the protocol
Cardiac function
LVEF ≥50% by either an ECHO or MUGA within 28 days before the trial starts
Has adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to initiation of trial intervention as specified in the protocol. Has an LVEF ≥50% by either an ECHO or MUGA within 28 days before the trial starts.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify